(Information sent by the signatory company)
It is indicated for patients undergoing allogeneic hematopoietic stem cell transplantation. Prodigy is the first company to join the MSK Therapeutics Accelerator. The launch of this accelerator program was announced at the MSK Life Sciences Innovation Summit held in New York City on January 26, 2024.
West Chester, Pennsylvania, February 6, 2024 – Prodigy and MSK have signed a sponsored research agreement under the MSK Therapeutics Accelerator program to evaluate Prodigy’s product candidate for improving outcomes in allogeneic transplant patients of hematopoietic stem cells (allogeneic HSCT). The MSK Therapeutics Accelerator project will be led by Jonathan Peled, Dr. med., Ph. D., attending physician, MSK.
Through their cutting-edge research, Dr. Peled and his team at MSK have significantly advanced the role of the microbiome in affecting outcomes in patients undergoing allogeneic HSCT. Dr. Peled’s work has revealed that patients undergoing allogeneic HSCT exhibit enterococcal dominance events and that such dominance events lead to worse overall survival and higher graft-versus-host disease (GVHD)-related mortality. Dr. Peled has previously shown in preclinical models that reestablishing the gut microbiome achieves profound results in mitigating disease severity.
In this collaboration, neutralizing antibodies to Enterococcus sp. will be evaluated. of Prodigy in preclinical GVHD models and product candidates will be developed to move into clinical development. Additionally, Prodigy is pleased to have Dr. Peled join and help create the company’s allogeneic HSCT Scientific Advisory Board (SAB).
In addition to sponsored research, MSK will provide expertise and institutional resources through the MSK Therapeutics Accelerator to help develop a drug candidate for patients undergoing allogeneic hematopoietic stem cell transplantation. MSK Therapeutics Accelerator is a collaborative program between MSK and technology and pharmaceutical companies aimed at advancing novel treatments throughout all phases of drug development. The program brings together innovative healthcare companies and MSK’s community of clinical and scientific experts to establish innovative collaborations that can have a tangible impact on cancer treatment or management.
Satish Chandran, CEO of Prodigy said: “We are delighted to collaborate and partner with the MSK Therapeutic Accelerator program and Dr. Peled to develop product/s for patients undergoing allogeneic HSCT. Given the significant morbidity and mortality associated with the disease, we It is up to everyone to find solutions that have the potential to save lives and return these patients to normal. We are very pleased with the strong preclinical proof-of-concept data for our product PROD-AH-001, (Hepatology, 2023) for hepatitis alcoholic beverage, which is currently being prepared for IND filing with the FDA.
Dr. Jonathan Peled from MSK said: “Patients treated with allogeneic HSCT experience the most extreme microbiome lesions observed in any clinical setting. There is an urgent need to develop approaches that can mitigate this and prevent the spread of potentially pathogenic bacteria. Our hypothesis “is that attenuating the spread of Enterococcus in the gastrointestinal tract will prevent bloodstream infections with this bacteria, in addition to potentially ameliorating GVHD.”
Dr. Chandran presented information about this important new collaboration at the MSK Life Sciences Innovation Summit in New York City on January 26, 2024.
About allogeneic hematopoietic stem cell transplantation
Allogeneic HSCT has the potential to cure malignant neoplasms, although it is associated with a high rate of complications and mortality. Allogeneic HSCT can lead to several complications, affecting different organs due to the intense conditioning regimen and the introduction of foreign immune cells. A major concern after allogeneic HSCT is graft-versus-host disease (GVHD), in which the donor’s immune cells attack the recipient, being a major cause of morbidity and non-relapse mortality in this patient population. There is a clear need for treatments capable of improving outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.
About Prodigy Biotech, Inc.
Prodigy Biotech is a private biopharmaceutical company specialized in developing products using its polyclonal immunoglobulin Y technology to selectively edit the microbiome, while avoiding harmful effects on commensal microflora. The versatility of avian antibodies, IgY, provides the possibility of specifically neutralizing pathogens not only of bacteria, but also viruses, fungi, endotoxins and even secreted human proteins, such as cytokines and chemokines. A goal-agnostic approach and strategic collaborations with leading researchers in the microbiome field have allowed Prodigy to create a diverse project ranging from gut microbiome modulation in alcohol liver disease (ALD) to lung microbiome modulation in chronic obstructive pulmonary disease (COPD).
https://www.prodigybiotech.com
Contact
Contact Name: Satish Chandran
Contact description: Chief Executive Officer
Contact phone: (609) 672-0793
